The failure of glycosylation also results in the reduced expression of MPL [96,97], which tracks with an increase in the JAK2 V617F MAB [83], and actually tracks better with the MPN disease phenotype than the JAK2 V617F MAB [3]. Here, JAK2 is linked to myeloproliferative neoplasm.